Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29020676 | 0.83 | MAPT (0.50) | POLBGPR119TP53THRBMEN1 | |
| SCHEMBL30385525 | 0.83 | MAPT (0.50) | POLBGPR119TP53THRBMEN1 | |
| SCHEMBL22657809 | 0.82 | POLB (0.51) | POLBGPR119DYRK2TP53THRB | |
| SCHEMBL22672840 | 0.81 | POLB (0.47) | POLBGPR119DYRK2TP53THRB | |
| SCHEMBL22657821 | 0.81 | POLB (0.49) | POLBGPR119DYRK2TP53THRB | |
| SCHEMBL25210145 | 0.77 | MAPT (0.51) | GPR119MEN1MAPTTSHRKMT2A | |
| SCHEMBL30720125 | 0.77 | MEN1 (0.48) | GPR119CFTRTP53MEN1MAPT | |
| SCHEMBL22657853 | 0.75 | POLB (0.44) | POLBGPR119TP53THRBLMNA | |
| SCHEMBL3089588 | 0.74 | MEN1 (0.52) | POLBGPR119TP53THRBMEN1 | |
| SCHEMBL22657961 | 0.74 | GPR119 (0.36) | POLBGPR119CFTRTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | Suzhou Four Health Pharmaceuticals Co., Ltd. (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-3969450-B1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SUZHOU FOUR HEALTH PHARMACEUTICALS CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3969450-B1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SUZHOU FOUR HEALTH PHARMACEUTICALS CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20220227757-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SHUZHOU FOUR HEALTH PHARMACEUTICALS CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| WO-2020229595-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | MOLECULAR TARGETED RADIOPHARMACEUTICALS HOLDING GMBH (MTR) (DE) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020229595-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | MOLECULAR TARGETED RADIOPHARMACEUTICALS HOLDING GMBH (MTR) (DE) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | PARP1, PARP3, PARP2 | POLB 78/4885GPR119 4713/4885DYRK2 331/4885 |
| US-20220227757-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | POLB 38/4885GPR119 4403/4885DYRK2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.